Abbott boasts 54 straight years of dividend growth, and plans to spin off its troubled nutrition division could lead to a re-rating of the stock. McDonald's has raised its dividend for 50 years, and the stock should rebound further if turnaround efforts continue to improve results.
Abbott's Encantor system includes software-guided deployment technology designed to help optimize valve expansion to the patient's unique anatomy, supporting precise implantation and consistent valve performance Encantor early feasibility study data will be presented at PCR London Valves 2026 ABBOTT PARK, Ill., Nov. 19, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has initiated the VOYAGER CE clinical trial evaluating the safety and efficacy of its investigational Encantor™ transcatheter aortic valve implantation (TAVI) software-guided balloon-expandable system for treating symptomatic severe aortic stenosis.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
The SCHD dividend ETF has extended its year-to-date lead over SPY to more than 20%, despite recent market volatility. October was SCHD's best month of 2026, with a nearly 10% gain; 43 holdings have returned more than twice SPY year-to-date. Twelve holdings announced dividend increases averaging 7.21%, alongside one special dividend; several delivered double-digit hikes.
On November 16, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year with its stock price reflecting a
AlTi Global Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,789 shares of the healthcare product maker's stock after acquiring an additional 11,649 shares during the period. AlTi
Allworth Financial LP raised its holdings in Abbott Laboratories (NYSE: ABT) by 5.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 269,783 shares of the healthcare product maker's stock after purchasing an additional 14,018 shares during the quarter. Allworth Financial